CCNE1 copy number is a biomarker for response to combination WEE1-ATR inhibition in ovarian and endometrial cancer models
Summary: CCNE1-amplified ovarian cancers (OVCAs) and endometrial cancers (EMCAs) are associated with platinum resistance and poor survival, representing a clinically unmet need. We hypothesized that dysregulated cell-cycle progression promoted by CCNE1 overexpression would lead to increased sensitiv...
Main Authors: | Haineng Xu, Erin George, Yasuto Kinose, Hyoung Kim, Jennifer B. Shah, Jasmine D. Peake, Benjamin Ferman, Sergey Medvedev, Thomas Murtha, Carter J. Barger, Kyle M. Devins, Kurt D’Andrea, Bradley Wubbenhorst, Lauren E. Schwartz, Wei-Ting Hwang, Gordon B. Mills, Katherine L. Nathanson, Adam R. Karpf, Ronny Drapkin, Eric J. Brown, Fiona Simpkins |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-09-01
|
Series: | Cell Reports Medicine |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2666379121002524 |
Similar Items
-
Treatment for ovarian clear cell carcinoma with combined inhibition of WEE1 and ATR
by: Wenwen Chien, et al.
Published: (2023-04-01) -
Differential Effects of Combined ATR/WEE1 Inhibition in Cancer Cells
by: Gro Elise Rødland, et al.
Published: (2021-07-01) -
Clinical Candidates Targeting the ATR–CHK1–WEE1 Axis in Cancer
by: Lukas Gorecki, et al.
Published: (2021-02-01) -
Motor neuron and pancreas homeobox 1/HLXB9 promotes sustained proliferation in bladder cancer by upregulating CCNE1/2
by: Mingkun Chen, et al.
Published: (2018-07-01) -
CCNE1 is a predictive and immunotherapeutic indicator in various cancers including UCEC: a pan-cancer analysis
by: Xingyu Zheng, et al.
Published: (2023-03-01)